This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Raymond B. Weiss, MD
Walter Reed Army Medical Center Washington, DC

JAMA. 1993;270(22):2685.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Some of the Cancer and Leukemia Group B studies do prohibit use of certain concurrent medications. These prohibitions are usually limited to corticosteroids in such malignancies as myeloma, breast carcinoma, and lymphomas. Dr Wilson asks if our audit process critiques protocol deviations where a prohibited drug is given anyway. The answer is, "Yes indeed," and when this occurs, it is coded as a major deviation. This deviation occurs most often in use of dexamethasone as an antiemetic to be administered with chemotherapy. There are a number of such additional issues that could have been evaluated in our analysis of the audit reports generated during the past 11 years. However, we chose to assess those protocol deviations and administrative deficiencies that we thought were particularly important. Although I cannot provide Wilson with a precise figure of how often this sort of protocol deviation occurs, a reasonable estimate is something . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?